Share-based Payment Arrangement, Expense of Carisma Therapeutics Inc. from 31 Mar 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Carisma Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2014 to 30 Sep 2025.
  • Carisma Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $421,000, a 62% decline year-over-year.
  • Carisma Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,212,000, a 40% decline year-over-year.
  • Carisma Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,649,000, a 58% increase from 2023.
  • Carisma Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,316,000, a 742% increase from 2022.
  • Carisma Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $275,000, a 95% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Carisma Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,212,000 $421,000 -$694,000 -62% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $2,906,000 $431,000 -$194,000 -31% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $3,100,000 $508,000 -$549,000 -52% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $3,649,000 $852,000 -$21,000 -2.4% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $3,670,000 $1,115,000 +$267,000 +31% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $3,403,000 $625,000 +$295,000 +89% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $3,108,000 $1,057,000 +$792,000 +299% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $2,316,000 $873,000 +$833,000 +2082% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $1,483,000 $848,000 +$760,000 +864% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $723,000 $330,000 +$272,000 +469% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $451,000 $265,000 +$176,000 +198% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $275,000 $40,000 -$1,718,000 -98% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $1,993,000 $88,000 -$1,080,000 -92% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $3,073,000 $58,000 -$1,201,000 -95% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $4,274,000 $89,000 -$869,000 -91% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $5,143,000 $1,758,000 +$1,352,000 +333% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $3,791,000 $1,168,000 +$715,000 +158% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $3,076,000 $1,259,000 +$768,000 +156% 01 Apr 2021 30 Jun 2021 10-Q/A 25 Aug 2022 2022 Q2
Q1 2021 $2,308,000 $958,000 +$551,000 +135% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $1,757,000 $406,000 +$79,000 +24% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $1,678,000 $453,000 +$224,000 +98% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $1,454,000 $491,000 +$136,000 +38% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $1,318,000 $407,000 +$81,000 +25% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $1,237,000 $327,000 -$434,000 -57% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $1,671,000 $229,000 -$19,000 -7.7% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $1,690,000 $355,000 +$292,000 +463% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $1,398,000 $326,000 +$115,000 +55% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $1,283,000 $761,000 01 Oct 2018 31 Dec 2018 10-K 15 Mar 2021 2020 FY
Q3 2018 $248,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $63,000 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $211,000 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q3 2016 $1,700,000 +$1,700,000 20 Sep 2016 10-K 01 Mar 2019 2018 FY
Q3 2015 $0 -$272,000 -100% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2015 2015 Q3
Q2 2015 $0 -$5,000 -100% 01 Apr 2015 30 Jun 2015 10-Q 13 Aug 2015 2015 Q2
Q1 2015 $0 -$17,000 -100% 01 Jan 2015 31 Mar 2015 10-Q 30 Apr 2015 2015 Q1
Q3 2014 $272,000 01 Jul 2014 30 Sep 2014 10-Q 04 Nov 2015 2015 Q3
Q2 2014 $5,000 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $17,000 01 Jan 2014 31 Mar 2014 10-Q 30 Apr 2015 2015 Q1

Carisma Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,649,000 +$1,333,000 +58% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $2,316,000 +$2,041,000 +742% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $275,000 -$4,868,000 -95% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $5,143,000 +$3,386,000 +193% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
2020 $1,757,000 +$520,000 +42% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $1,237,000 -$46,000 -3.6% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $1,283,000 -$98,000 -7.1% 01 Jan 2018 31 Dec 2018 10-K 15 Mar 2021 2020 FY
2017 $1,381,000 01 Jan 2017 31 Dec 2017 10-K 16 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.